Certainly, translating our peptide-devoted approach to BcR IGs commonly expressed in CLL could lead to a more informative patient classification focused on analyzing the gene expression profiles and deregulated genes associated with specific BcR IG rearrangements. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.